In-Office Tympanostomy Tube Placement in Children (OTTER)

AOM - Acute Otitis Media Clinical Trial

— OTTER  

Official title:

A Prospective, Single-arm, Multicenter Study to Evaluate Effectiveness and Safety of Tympanostomy Tube Placement Using the Tula Iontophoresis and Tube Delivery Systems for Children in an Office Setting.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03323736
• Other study ID #: CPR007001
• Status: Completed
• Phase: Phase 3
• Start date: October 31, 2017
• Est. completion date: March 25, 2021

Study information

• Verified date: May 2022
• Source: Tusker Medical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, single-arm, multicenter study to evaluate effectiveness and safety of Tymbion iontophoresis and tympanostomy tube placement using the Tula Iontophoresis and Tube Delivery Systems for children in an office setting.

Description:

The objective of this study is to evaluate effectiveness and safety of tympanostomy tube (TT) placement in children following local anesthesia in a physician's clinic setting (henceforth referred to as 'in-office'). Local anesthesia using Tymbion, a lidocaine-based anesthetic, is delivered by the Tula Iontophoresis System (IPS) and TT placement is implemented by the Tula Tube Delivery System (TDS).

The IPS will be used to facilitate anesthetic delivery to the tympanic membrane (TM). The Iontophoresis System consists of an Iontophoresis Control Unit, Iontophoresis Earsets and a return electrode patch. The Control Unit monitors and delivers a fixed amount of charge (ie, dose) to the patient through the Earsets(s) and alerts the operator when charge delivery is complete. The lidocaine-based solution used for local anesthesia of the TM is Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine).

The TDS is a mechanical device that integrates a myringotomy blade, tympanostomy tube and tube inserter for TT placement with a user-controlled activation. The study will use the TDS with a grommet-type tube.

This pivotal study will include up to 422 children ages 6 months through 12 years indicated for tympanostomy tube placement enrolled at approximately 15 to 25 investigational centers in the US and Canada. The pivotal cohort consists of 222 subjects. In addition, up to 100 subjects will be enrolled as lead-in procedures in the OR using the TDS and up to 100 subjects will be enrolled as lead-in procedure in-office (using IPS and TDS) as the surgeons' initial experience with the technology prior to enrolling into the pivotal cohort.

All pivotal and lead-in subjects will follow the same study protocol assessments and visit schedule consisting of a screening visit, procedure visit and 3-week, 6 month, 12 month, 18 month, and 24 month post-procedure follow-up visits. Lead-in procedures will be analyzed separately from the pivotal pediatric cohort.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 370
• Est. completion date: March 25, 2021
• Est. primary completion date: February 28, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 12 Years

Eligibility

Inclusion Criteria:

1. Males or females at least 6 months old through 12 years old at time of consent

2. Indication for tympanostomy tube insertion per Clinical Practice Guideline

3. Behavioral capacity and cooperative temperament to undergo an awake procedure, based on physician judgment (not applicable to OR Lead-In subjects)

4. Subject's parent/guardian and subject are able and willing to comply with the protocol and attend all study visits

5. Subject's parent/guardian and subject are able and willing to provide informed consent or assent as age appropriate

Exclusion Criteria:

1. Significantly atrophic, retracted, bimeric, monomeric or atelectatic tympanic membrane

2. Perforated tympanic membrane

3. Otitis externa

4. Active or recent conditions of the tympanic membrane (eg, prior myringotomy with incomplete wound healing or re-epithelization)

5. Hemotympanum

6. Damaged/denuded skin in the auditory canal

7. Cerumen impaction resulting in a significant amount of cleaning required to visualize the tympanic membrane potentially causing abrasion or irritation to the external ear canal

8. Anatomy that precludes sufficient visualization of and access to the tympanic membrane

9. Anatomy that necessitates tympanostomy tube placement in the posterior half of the tympanic membrane

10. History of sensitivity or allergic reaction to lidocaine HCl, tetracaine, epinephrine, or any hypersensitivity to local anesthetics of the amide type, or any component of the anesthetic drug formulation (not applicable to OR Lead-In subjects)

11. Familial history of insensitivity to lidocaine or other local anesthetics of the amide type (eg, history of inadequate anesthesia with dental numbing agents). (not applicable to OR Lead-In subjects)

12. Electrically sensitive medical support systems (eg, pacemakers, defibrillators, cochlear implants)

13. Other conditions that would preclude performing the study procedure including iontophoresis system ear plug incompatibility.

14. Health conditions that, in the opinion of the investigator, would present undue risk to the subject, based on device/anesthetic drug product label warnings and precautions.

15. Subject is 4 years or older and not able to complete all baseline assessments. Subject is younger than 4 years and not able to complete all baseline assessments, not including audiometry.

Related Conditions & MeSH terms

• AOM - Acute Otitis Media
• OME - Otitis Media With Effusion
• Otitis
• Otitis Media
• Otitis Media with Effusion

Intervention

Combination Product:
• Iontophoresis & tube placement
Subjects will receive active Tymbion iontophoresis and will have tubes placed in-office using the Tube Delivery System in all ears indicated for tube placement.

Device:
• Tube placement
Subjects will have tubes placed in the OR using the Tube Delivery System in all ears indicated for tube placement.

Locations

Country	Name	City	State
Canada	British Columbia Children's Hospital	Vancouver	British Columbia
United States	Ear Nose and Throat Specialists of Abilene	Abilene	Texas
United States	Albany ENT & Allergy Services	Albany	New York
United States	Specialty Physician Associates	Bethlehem	Pennsylvania
United States	California Head and Neck Specialists	Carlsbad	California
United States	Charlotte Ear Eye Nose & Throat Associates, PA	Charlotte	North Carolina
United States	South Florida Pediatric Otolaryngology	Fort Lauderdale	Florida
United States	Collin County ENT	Frisco	Texas
United States	Frisco ENT for Children	Frisco	Texas
United States	Connecticut Children's Medical Center	Hartford	Connecticut
United States	Nemour's Children's Specialty Care	Jacksonville	Florida
United States	Advanced ENT & Allergy	Louisville	Kentucky
United States	South Carolina Ear Nose and Throat	Lugoff	South Carolina
United States	Yale School of Medicine, Section of Otolaryngology	New Haven	Connecticut
United States	Columbia University Medical Center	New York	New York
United States	Carolina Ear Nose and Throat Clinic	Orangeburg	South Carolina
United States	Sacramento ENT	Roseville	California
United States	Ear Medical Group	San Antonio	Texas
United States	Camino Ear Nose & Throat Clinic	San Jose	California

Sponsors (1)

Lead Sponsor	Collaborator
Tusker Medical

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Procedural Success:	Count (and percentage) of subjects in the pivotal cohort with successful placement of Tusker Medical tympanostomy tubes in all indicated ears in an office procedure. Note: the primary endpoint applies only to the Pivotal Cohort, and not to the OR Lead-In or Office Lead-In cohorts.	Day of Procedure (Day 0) Immediately following tube placement
Primary	Tube Placement Tolerability	Mean subject-reported pain score following TDS tube placement using the Faces Pain Scale-Revised (FPS-R) (pivotal cohort children ages 5 and older only). The FPS-R has 6 faces which permits scaling to a 0-to-10 scoring system in intervals of 2 (ie 0, 2, 4, 6, 8 and 10), where 0 represents 'no pain' and 10 represents 'very much pain'. Note- the primary endpoint applies only to the Pivotal Cohort, and not to the OR Lead-In or Office Lead-In cohorts.	Day of Procedure (Day 0) Immediately following tube placement
Secondary	Tube Patency	Count (and percentage) of subjects in the pivotal cohort, in which a Tusker Medical tube was successfully placed, with functionally patent tube(s) at the 3-week post-procedure follow-up visit.; Note- thus secondary endpoint applies only to the Pivotal Cohort, and not to the OR Lead-In or Office Lead-In cohorts.; Note - This endpoint includes subjects for which at least 1 ear had successful tube placement. For bilateral subjects, they may be considered a non-successful procedure if only 1 ear had successful tube placement, however would be evaluated for the Tube Patency endpoint for the ear that was successful.	3 Weeks Post Procedure
Secondary	Tube Retention	Count (percentage) of subjects in the pivotal cohort, in which a Tusker Medical tube(s) was successfully placed, with presence of a Tusker Medical tube across the TM in all successfully treated ears at the 3-week post-procedure follow-up visit.; Note- the secondary endpoint applies only to the Pivotal Cohort, and not to the OR Lead-In or Office Lead-In cohorts.; Note - This endpoint includes subjects for which at least 1 ear had successful tube placement. For bilateral subjects, they may be considered a non-successful procedure if only 1 ear had successful tube placement, however would be evaluated for the Tube Retention endpoint for the ear that was successful.	3 Weeks Post Procedure
Secondary	Anesthesia Effectiveness	Count (percentage) of subjects in the pivotal cohort, who completed iontophoresis for all indicated ears, with adequate anesthesia for TT placement in all treated ears as determined by physician's evaluation of TM anesthesia prior to tube placement.; Note- the secondary endpoint applies only to the Pivotal Cohort, and not to the OR Lead-In or Office Lead-In cohorts.	Day of Procedure (Day 0)